Lataa...
Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
BACKGROUND: The selective Janus-activated kinase inhibitor ruxolitinib (rux) is now widely used to treat myelofibrosis and polycythemia vera due to its remarkable effect of reducing splenomegaly and improving constitutional symptoms. With opportunistic infections secondary to rux constantly reported...
Tallennettuna:
| Julkaisussa: | Infect Drug Resist |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7532060/ https://ncbi.nlm.nih.gov/pubmed/33061478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S267997 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|